Daphne Zohar is the founder and chief executive officer of PureTech and a member of the board of directors. She has also served as the founding chief executive officer of a number of PureTech’s Founded Entities. A successful entrepreneur, Ms. Zohar created PureTech, assembling a leading team to help implement her vision for the Company, and was a key participant in fundraising, business development and establishing the underlying programs and platforms that have resulted in PureTech’s substantial pipeline, which is comprised of 26 therapeutics and therapeutic candidates being advanced via the Company’s Wholly Owned Pipeline and Founded Entities, including two that have been cleared for marketing by the U.S. Food and Drug Administration and granted marketing authorization in the European Economic Area. Ms. Zohar has been recognized as a top leader and innovator in biotechnology by a number of sources, including EY, BioWorld, MIT Technology Review, The Boston Globe and Scientific American. 

Joe Bolen, PhD, is chief scientific officer at PureTech, where he works with the Company’s discovery and preclinical team to identify and pursue promising new technologies. Dr. Bolen has more than 30 years of industry and research experience and has been at the forefront of cancer and immunology research. Dr. Bolen most recently oversaw all aspects of research and development for Moderna Therapeutics as president and chief scientific officer. Previously, he was chief scientific officer and global head of oncology research at Millennium: The Takeda Oncology Company. Prior to joining Millennium in 1999, Dr. Bolen held senior R&D positions at Hoechst Marion Roussel, Schering-Plough and Bristol-Myers Squibb. He began his career at the National Institutes of Health (NIH), where he contributed to the discovery of a class of proteins known as tyrosine kinase oncogenes as key regulators of the immune system. Dr. Bolen graduated from the University of Nebraska with a BS degree in microbiology and chemistry and a PhD. in immunology and conducted his postdoctoral training in molecular virology at the Kansas State University Cancer Center.

Bharatt Chowrira, PhD, JD, has been the president and chief of business and strategy at PureTech since March 2017 and is a member of the board of directors. Prior to joining PureTech, Dr. Chowrira was the president of Synlogic, Inc., a biopharmaceutical company focused on developing synthetic microbiome-based therapeutics, from September 2015 to February 2017, where he oversaw and managed corporate and business development, alliance management, financial, human resources, intellectual property and legal operations. Prior to joining Synlogic, Dr. Chowrira was the chief operating officer of Auspex Pharmaceuticals Inc., from 2013 to 2015, which was acquired by Teva Pharmaceuticals in the Spring of 2015. Previously, he was president and chief executive officer of Addex Therapeutics Ltd., a biotechnology company publicly traded on the SIX Swiss Exchange, from 2011 to 2013. Prior to that, Dr. Chowrira held various leadership and management positions at Nektar Therapeutics (chief operating officer), Merck & Co, or Merck (vice president), Sirna Therapeutics (general counsel; acquired by Merck) and Ribozyme Pharmaceuticals (chief patent counsel). Dr. Chowrira is a member of the board of directors of Vedanta Biosciences, Inc., and Vor Biopharma, Inc. Dr. Chowrira received a JD from the University of Denver’s Sturm College of Law, a PhD in molecular biology from the University of Vermont College of Medicine, an MS in molecular biology from Illinois State University and a BS in microbiology from the UAS, Bangalore, India.

Eric Elenko, PhD, is the chief innovation officer at PureTech where he has led the development of a number of programs, including Akili Interactive Labs, Inc., Gelesis, Inc., Karuna Therapeutics, Inc. and Sonde Health, Inc. Prior to joining PureTech, Dr. Elenko was a consultant with McKinsey and Company where he advised senior executives of both Fortune 500 and specialty pharmaceutical companies on a range of issues such as product licensing, mergers and acquisitions, research and development strategy and marketing. Dr. Elenko received his BA in biology from Swarthmore College and his PhD in biomedical sciences from the University of California, San Diego.

Joep Muijrers, PhD, is the chief of portfolio strategy at PureTech. Dr. Muijrers has two decades of experience in corporate and capital finance, specifically focused on investment, M&A, portfolio management, strategic asset allocation, financial and regulatory reporting and fundraising. Prior to joining PureTech, he was a portfolio manager and partner at LSP (Life Sciences Partners), a specialist investor group with sole focus on investing in healthcare and life sciences, in the Netherlands and in Boston. At LSP, Dr. Muijrers was responsible for investing in publicly traded companies, a strategy that generated a total return in excess of 900 percent, more than twice the return of the Nasdaq Biotechnology Index during the same period (Q2 2008 – Q1 2018). Notable investments included companies that were acquired by large pharma (Ablynx, CoLucid, InterMune, Kite Pharma, NeuroDerm) and/or became leaders in their respective areas of activity (Evotec, Genmab, GW Pharmaceuticals, MorphoSys, Neurocrine). Prior to joining LSP, he held the position of director corporate finance and capital markets at Fortis Bank, currently part of ABN AMRO. Dr. Muijrers is currently a member of the board of directors of Alivio Therapeutics, Inc., Entrega, Inc., Follica, Incorporated and Sonde Health, Inc. Dr. Muijrers holds a PhD degree in molecular biology from the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany and an MS in biochemistry from the University of Nijmegen, the Netherlands.

Stephen Muniz, Esq., is the chief operating officer at PureTech and has served as a member of PureTech’s board of directors since 2015. Prior to joining PureTech, Mr. Muniz was a partner in the corporate department of Locke Lord LLP, where he practiced law for 10 years. Mr. Muniz’s practice at Locke Lord LLP focused on the representation of life science venture funds as well as their portfolio companies in general corporate matters and in investment and liquidity transactions.

Prior to joining Locke Lord LLP, Mr Muniz was a law clerk to The Honorable Raya Dreben at the Massachusetts Appeals Court. He was also a Kauffman Entrepreneur Fellow, a program sponsored by the Kauffman Foundation. Mr. Muniz also sits on the board of directors of Entrega, Inc., Follica, Incorporated, and Alivio Therapeutics, Inc. He previously served on the board of directors of Karuna Therapeutics, Inc. and Gelesis, Inc. Mr. Muniz has a BA in economics and accounting from The College of the Holy Cross and a JD from the New England School of Law (NESL) where he graduated summa cum laude. Mr. Muniz was valedictorian of the 1997 NESL Commencement and has been awarded the Amos L. Taylor Award for Excellence in Scholarship, the New England Scholar Award and the NESL Trustee Scholar Award.